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Antibiotic resistance is a very important challenge and in 2011 the 
World Health Organization (WHO) considered it as one of the most 
important global health problems [1].
The emergence of drug resistance of Gram-positive pathogens 
such as Staphylococcus aureus is currently a health problem of global 
significance and the overuse of antibiotics, both in human and animal 
populations, played an important part in the beginning of drug-
resistant strains.
S. aureus is a very versatile pathogen that can cause a wide variety 
of infectious diseases ranging from superficial skin infections to life-
threatening endocarditis and sepsis [2]. Its versatility as a pathogen is 
due to the wide arsenal of weapons (virulence factors) that it possesses 
[3]. 
The virulence factors include the cell-wall associated proteins called 
MSCRAMMs (microbial surface components recognizing adhesive 
matrix molecules) that can promote the adhesion to host proteins, for 
example, the fibronectin that is very common in host tissues. The cell-
wall associated proteins are necessary for host colonization, invasion, 
immune evasion and biofilm formation [4]. The biofilms, multi-
stratified bacterial communities that grow on a biological or artificial 
surface, are responsible for chronic infectious diseases and for device 
or biomaterial associated infections, and are more resistant to host 
immune defence system and to conventional antibiotics [5]. 
The cell-wall associated proteins are covalently linked to the 
peptidoglycan through the enzymatic activity of so-called sortases. 
These sortases are membrane-bound transpeptidases that cleave the 
peptide bond between the threonine (Thr) and the glycine residues of 
a LPxTG motif, and catalyze the formation of an amide bond between 
the carboxylic group of Thr residue and the free amino end of a 
pentaglycine cross bridge in peptidoglycan precursors [6].
The Sortase A (SrtA) is the most well studied member of the 
sortase family. S. aureus strains lacking the SrtA gene do not present 
the LPxTG proteins at the cell surface. As a consequence, SrtA mutant 
strains are less virulent than wild strains and they are defective in the 
establishment of infections [7]. There are around 20 staphylococcal 
proteins that carry a C-terminal LPxTG motif, these include protein A 
(Spa), two fibronectin binding proteins (FnbpA and FnbpB) and two 
clumping factors (ClfA and ClfB). For some of these proteins a direct 
role in biofilm formation has been reported [8]. 
There is an urgent need of anti-virulence agents effective in the 
prevention or eradication of biofilms that are intrinsically resistant 
to conventional antibiotics. If we consider that the first step of 
staphylococcal pathogenesis and of biofilm formation is the bacterial 
adhesion, promoted by the surface exposed proteins at the cell wall, 
we believe that new anti-virulence agents could be developed by using 
as a target the enzyme responsible of linking surface exposed proteins 
rather than any single surface protein involved in the mechanism of 
virulence [9]. Therefore, the SrtA is a good target to design novel anti-
infective drugs and SrtA inhibitors could act as anti-adhesion agents 
useful to prevent a virulence mechanism as biofilm formation. 
Many inhibitors of StrA, afforded via high-throughput screening of 
libraries of compounds (synthetic or natural), have been identified, and 
most of them are useful for explaining the action model of the enzyme. 
Some of them are, instead, potential leading compounds [10]. The 
efficacy of the most interesting SrtA inhibitors needs to be evaluated 
by in vivo models of infection (sepsis, abscess, septic arthritis and 
endocarditis), but a simple methodology in vitro, such as inhibition of 
biofilm formation, could represent a first assessment of anti-virulence 
properties of novel inhibitors of SrtA.
There are some other important aspects concerning SrtA on 
which attention should be focused: other Gram positive pathogens 
like enterococci or streptococci possess the enzyme SrtA; SrtA is 
not indispensable for microbial growth and survival so the SrtA 
inhibitors have a limited antibacterial activity that could minimize the 
development of resistance; sortases are membrane enzymes that could 
be more easily targeted by inhibitors respect to intracellular targets 
[11].
The goal of the research in this field is to obtain novel SrtA inhibitors 
that could interfere with Gram positive virulence mechanisms including 
adhesion to host tissues, evasion of host defence, as phagocytosis or 
opsonisation, and the biofilm formation.
The possibility of using novel agents targeting virulence mechanisms 
and biofilm formation (anti-virulence agents) in combination 
with current antibiotics is a potential new therapeutic strategy in 
the treatment of bacterial chronic infections and can contribute to 
overcoming antibiotic resistance, which is considered one of today’s 
most important global challenges.
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